<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": italic;} Open Forum Infect DisOpen Forum Infect DisofidOpen Forum" exact="Infectious" post="Diseases2328-8957Oxford University PressUS pmcid: 7243378 doi: 10.1093/ofid/ofaa146ofaa146 : Major"/>
 <result pre="Outcomes in a Prospective Cohort of Adults Hospitalized for Community-Acquired" exact="Pneumonia" post="http://orcid.org/0000-0001-5242-2967LuiGrace1ToHeather K W2LeeNelson3ChanRenee W Y4LiTimothy2WongRity Y K2HuiDavid S C1IpMargaret5[1],"/>
 <result pre="Department of Medicine and Therapeutics, Stanley Ho Centre for Emerging" exact="Infectious" post="Diseases, The Chinese University of Hong KongHong Kong[2], Department"/>
 <result pre="Abstract Abstract Background Understanding local epidemiology and etiologies of community-acquired" exact="pneumonia" post="in hospitalized patients is crucial for determining the appropriateness"/>
 <result pre="the etiologies, severity, and outcomes in adults hospitalized for community-acquired" exact="pneumonia" post="and to study the impact of empirical antibiotic therapy"/>
 <result pre="a prospective observational cohort study involving adults hospitalized for community-acquired" exact="pneumonia" post="in Hong Kong. Sputum, nasopharyngeal aspirate, blood, and urine"/>
 <result pre="Kong. Sputum, nasopharyngeal aspirate, blood, and urine were collected for" exact="bacterial" post="culture, molecular tests for detection of viruses and atypical"/>
 <result pre="for bacterial culture, molecular tests for detection of viruses and" exact="atypical" post="pathogens, and antigen tests. Multivariable logistic regression model and"/>
 <result pre="(interquartile range, 61–80) years, 66% were male, 57% had underlying" exact="chronic" post="illnesses, 13% had CURB-65 score ≥3, and 10% had"/>
 <result pre="Mycoplasma pneumoniae (1.2%) were the most common bacterial, viral, and" exact="atypical" post="pathogens, respectively. Nonadherence to local empirical antibiotic treatment guidelines"/>
 <result pre="(≥7 days) and higher mortality, after adjustment for age, underlying" exact="chronic" post="illness, and disease severity. Conclusions Adherence to treatment guidelines"/>
 <result pre="higher mortality, after adjustment for age, underlying chronic illness, and" exact="disease" post="severity. Conclusions Adherence to treatment guidelines was associated with"/>
 <result pre="provided evidence for the use of doxycycline for coverage of" exact="atypical" post="pathogens in nonsevere pneumonia. In this prospective study involving"/>
 <result pre="shorter hospitalization and improved survival. Our findings provided evidence for" exact="atypical" post="pathogen coverage with doxycycline, which was less evaluated in"/>
 <result pre="with doxycycline, which was less evaluated in other cohorts. community-acquired" exact="pneumonia" post="length of stay mortality treatment guidelines Funding Health and"/>
 <result pre="treatment guidelines Funding Health and Medical Research Fund10.13039/501100005847 CU-17-A16 page-count:" exact="Pneumonia" post="and lower respiratory tract infections caused 2.6 million deaths"/>
 <result pre="Funding Health and Medical Research Fund10.13039/501100005847 CU-17-A16 page-count: Pneumonia and" exact="lower" post="respiratory tract infections caused 2.6 million deaths in 2017"/>
 <result pre="Health and Medical Research Fund10.13039/501100005847 CU-17-A16 page-count: Pneumonia and lower" exact="respiratory" post="tract infections caused 2.6 million deaths in 2017 globally,"/>
 <result pre="Medical Research Fund10.13039/501100005847 CU-17-A16 page-count: Pneumonia and lower respiratory tract" exact="infections" post="caused 2.6 million deaths in 2017 globally, and it"/>
 <result pre="cause of death worldwide [1]. The annual incidence of community-acquired" exact="pneumonia" post="(CAP) in the United States was 25 cases per"/>
 <result pre="differ in Asia from other regions of the world [3]." exact="Local" post="surveillance data on the aetiologies and susceptibility patterns of"/>
 <result pre="bundle of treatment guidelines for the management of various common" exact="infectious diseases" post="was formulated and published in 2017 [5]. It would"/>
 <result pre="METHODS Study Design We performed a prospective, observational study involving" exact="adult" post="patients admitted for CAP to an acute care hospital"/>
 <result pre="observational study involving adult patients admitted for CAP to an" exact="acute" post="care hospital in Hong Kong. Disease severity, antibiotic treatment,"/>
 <result pre="for CAP to an acute care hospital in Hong Kong." exact="Disease" post="severity, antibiotic treatment, and outcomes were documented. Sputum, nasopharyngeal"/>
 <result pre="admission for microbiological studies. The study was approved by the" exact="Joint" post="Chinese University of Hong Kong–New Territories East Cluster Clinical"/>
 <result pre="Kong–New Territories East Cluster Clinical Research Ethics Committee. Subjects All" exact="adult" post="patients with an admission diagnosis of CAP during the"/>
 <result pre="eligibility. Inclusion criteria included (1) age ≥18 years, (2) presence of" exact="respiratory" post="symptoms with or without fever, and (3) evidence consistent"/>
 <result pre="symptoms with or without fever, and (3) evidence consistent with" exact="pneumonia" post="on chest radiograph. Patients were excluded if they had"/>
 <result pre="or without fever, and (3) evidence consistent with pneumonia on" exact="chest" post="radiograph. Patients were excluded if they had one of"/>
 <result pre="excluded if they had one of the following: (1) hospital-acquired" exact="pneumonia" post="(occurring ≥48 hours after admission; (2) recent hospitalization in"/>
 <result pre="conditions predisposing to noncommunity-acquired pathogens (including tracheostomy, percutaneous gastrostomy tube," exact="cancer" post="with neutropenia, solid or hematopoietic stem cell transplant within"/>
 <result pre="stem cell transplant within the previous 90 days, or human" exact="immunodeficiency" post="virus infection with CD4 &amp;lt;200 cells/mm3); or (5) clear alternative"/>
 <result pre="cell transplant within the previous 90 days, or human immunodeficiency" exact="virus infection" post="with CD4 &amp;lt;200 cells/mm3); or (5) clear alternative diagnosis. These"/>
 <result pre="transplant within the previous 90 days, or human immunodeficiency virus" exact="infection" post="with CD4 &amp;lt;200 cells/mm3); or (5) clear alternative diagnosis. These"/>
 <result pre="criteria were reported to be associated with drug-resistant pathogens for" exact="pneumonia" post="[2, 4]. Informed consent was obtained from each patient"/>
 <result pre="determined, with 1 point for each of confusion, urea &amp;gt;7 mmol/L," exact="respiratory" post="rate &amp;gt;30/minute, low systolic (&amp;lt;90 mmHg) or diastolic (&amp;lt;60 mmHg)"/>
 <result pre="day of admission and use of corticosteroid (for exacerbation of" exact="chronic" post="obstructive pulmonary disease or asthma) were documented. Clinical outcomes,"/>
 <result pre="admission and use of corticosteroid (for exacerbation of chronic obstructive" exact="pulmonary disease" post="or asthma) were documented. Clinical outcomes, including the 30-day,"/>
 <result pre="and use of corticosteroid (for exacerbation of chronic obstructive pulmonary" exact="disease" post="or asthma) were documented. Clinical outcomes, including the 30-day,"/>
 <result pre="Kong. Microbiologic investigations were performed as described with modifications [7]." exact="Blood" post="culture (BacT/Alert; bioMerieux, Marcy l’Etoile, France) was obtained and"/>
 <result pre="showing &amp;gt;25 white blood cells on high-power field with heavy/predominant" exact="bacterial" post="growth was included in the analysis. Acid-fast smear with"/>
 <result pre="included in the analysis. Acid-fast smear with culture of Mycobacterium" exact="tuberculosis" post="was performed if pulmonary tuberculosis was suspected. In-house multiplex"/>
 <result pre="Acid-fast smear with culture of Mycobacterium tuberculosis was performed if" exact="pulmonary tuberculosis" post="was suspected. In-house multiplex real-time polymerase chain reactions (PCRs)"/>
 <result pre="smear with culture of Mycobacterium tuberculosis was performed if pulmonary" exact="tuberculosis" post="was suspected. In-house multiplex real-time polymerase chain reactions (PCRs)"/>
 <result pre="(PCRs) were performed on nasopharyngeal aspirate for the detection of" exact="respiratory" post="viruses (influenza A, B, parainfluenza 1, 2 and 3,"/>
 <result pre="respiratory viruses (influenza A, B, parainfluenza 1, 2 and 3," exact="respiratory" post="syncytial virus, adenovirus, human metapneumovirus, and enterovirus/rhinovirus), Mycoplasma pneumoniae,"/>
 <result pre="prototype [10]. Urine samples were tested for Streptococcus pneumoniae and" exact="Legionella" post="pneumophila serogroup 1 using urinary antigen tests (Alere BinaxNOW;"/>
 <result pre="urinary antigen tests (Alere BinaxNOW; Abbott, Chicago, IL). Definitions Bacterial" exact="pneumonia" post="was defined as isolation of clinically significant pathogen from"/>
 <result pre="as isolation of clinically significant pathogen from sputum or blood" exact="bacterial" post="cultures, positive urine streptococcal and legionella antigen tests, or"/>
 <result pre="legionella antigen tests, or positive Mycoplasma or Chlamydophila PCR tests." exact="Viral" post="pneumonia was defined as positive respiratory viruses detected via"/>
 <result pre="antigen tests, or positive Mycoplasma or Chlamydophila PCR tests. Viral" exact="pneumonia" post="was defined as positive respiratory viruses detected via PCR."/>
 <result pre="or Chlamydophila PCR tests. Viral pneumonia was defined as positive" exact="respiratory" post="viruses detected via PCR. Polymicrobial pneumonia was defined as"/>
 <result pre="was defined as positive respiratory viruses detected via PCR. Polymicrobial" exact="pneumonia" post="was defined as the presence of 2 or more"/>
 <result pre="presence of 2 or more bacterial, viral, and/or mycobacterial pathogens." exact="Severe" post="pneumonia was defined as CURB-65 score ≥3 [6], and/or"/>
 <result pre="of 2 or more bacterial, viral, and/or mycobacterial pathogens. Severe" exact="pneumonia" post="was defined as CURB-65 score ≥3 [6], and/or requirement"/>
 <result pre="recommended. Empirical fluoroquinolone is only recommended for patients with documented" exact="allergy" post="to beta-lactam antibiotics. Statistical Analysis Continuous variables were presented"/>
 <result pre="of categorical variables between groups were performed using χ 2 or" exact="Fisher" post="exact tests, as appropriate. Comparisons of continuous variables between"/>
 <result pre="required to achieve a statistical power of 80%, at a" exact="Type I" post="error of 5% (PS: Power and Sample Size calculation"/>
 <result pre="Sample Size calculation software, version 3.0) [11–13]. RESULTS Baseline Characteristics," exact="Disease" post="Severity, and Microbiological Aetiologies From February 2017 to July"/>
 <result pre="patients (Table 1, Supplementary Figure 1). Fifty-two patients (20%) had" exact="viral pneumonia" post="(most commonly influenza viruses [12%] and rhinovirus [7%]), 38"/>
 <result pre="(Table 1, Supplementary Figure 1). Fifty-two patients (20%) had viral" exact="pneumonia" post="(most commonly influenza viruses [12%] and rhinovirus [7%]), 38"/>
 <result pre="commonly influenza viruses [12%] and rhinovirus [7%]), 38 (15%) had" exact="bacterial" post="pneumonia (S pneumoniae [12%], Hemophilus influenzae [7%], and M"/>
 <result pre="influenza viruses [12%] and rhinovirus [7%]), 38 (15%) had bacterial" exact="pneumonia" post="(S pneumoniae [12%], Hemophilus influenzae [7%], and M pneumoniae"/>
 <result pre="and 23 (9%) had polymicrobial pneumonia. Among those with a" exact="viral" post="pathogen identified (N = 73), 20 (27%) had a bacterial copathogen"/>
 <result pre="with a viral pathogen identified (N = 73), 20 (27%) had a" exact="bacterial" post="copathogen (S pneumoniae 13, H influenzae 6, and Legionella"/>
 <result pre="a bacterial copathogen (S pneumoniae 13, H influenzae 6, and" exact="Legionella" post="1). Bacterial pathogens in 93% of patients with bacterial"/>
 <result pre="and Legionella 1). Bacterial pathogens in 93% of patients with" exact="bacterial" post="pneumonia (excluding atypical pathogens) were susceptible to amoxicillin-clavulanate. Table"/>
 <result pre="Legionella 1). Bacterial pathogens in 93% of patients with bacterial" exact="pneumonia" post="(excluding atypical pathogens) were susceptible to amoxicillin-clavulanate. Table 1."/>
 <result pre="Bacterial pathogens in 93% of patients with bacterial pneumonia (excluding" exact="atypical" post="pathogens) were susceptible to amoxicillin-clavulanate. Table 1. Baseline Demographic,"/>
 <result pre="were susceptible to amoxicillin-clavulanate. Table 1. Baseline Demographic, Clinical Characteristics," exact="Disease" post="Severity, Treatment and Microbiological Aetiologies Age Group (years) Variables"/>
 <result pre="resident 4 (1.6%) 0 (0%) 2 (1.7%) 2 (1.8%) .765" exact="Chronic" post="illness, any 147 (57.0%) 3 (10.0%) 68 (59.1%) 76"/>
 <result pre="147 (57.0%) 3 (10.0%) 68 (59.1%) 76 (67.3%) &amp;lt;.001  Respiratory" exact="disease" post="54 (20.9%) 1 (3.3%) 23 (20.0%) 30 (26.5%) .02"/>
 <result pre="53 (20.5%) 1 (3.3%) 23 (20.0%) 29 (25.7%) .026  Coronary" exact="artery disease" post="35 (13.6%) 0 (0%) 13 (11.3%) 22 (19.5%) .014"/>
 <result pre="(20.5%) 1 (3.3%) 23 (20.0%) 29 (25.7%) .026  Coronary artery" exact="disease" post="35 (13.6%) 0 (0%) 13 (11.3%) 22 (19.5%) .014"/>
 <result pre="21 (8.1%) 1 (3.3%) 14 (12.2%) 6 (5.3%) .098  Congestive" exact="heart" post="failure 18 (7.0%) 0 (0%) 2 (1.7%) 16 (14.2%)"/>
 <result pre="18 (7.0%) 0 (0%) 2 (1.7%) 16 (14.2%) &amp;lt;.001  Chronic" exact="kidney disease" post="14 (5.4%) 0 (0%) 4 (3.5%) 10 (8.8%) .076"/>
 <result pre="(7.0%) 0 (0%) 2 (1.7%) 16 (14.2%) &amp;lt;.001  Chronic kidney" exact="disease" post="14 (5.4%) 0 (0%) 4 (3.5%) 10 (8.8%) .076"/>
 <result pre="oxygen 150 (58.1%) 7 (23.3%) 67 (58.3%) 76 (67.3%) &amp;lt;.001" exact="Noninvasive" post="ventilation 14 (5.4%) 0 (0%) 5 (4.3%) 9 (8.0%)"/>
 <result pre="0 (0%) 4 (3.5%) 3 (2.7%) .579 Empirical coverage for" exact="atypical" post="pathogensa 141 (54.7%) 24 (80.0%) 65 (56.5%) 52 (46.0%)"/>
 <result pre="3 (1.2%) 1 (3.3%) 0 (0%) 2 (1.8%) .229  Mycobacterium" exact="tuberculosis" post="5 (1.9%) 1 (3.3%) 4 (3.5%) 0 (0%) .137"/>
 <result pre="(n = 7, 2.7%). bExpectorated sputum and blood samples were obtained for" exact="bacterial" post="culture in 181 (70.2%) and 173 (67.1%) of patients,"/>
 <result pre="testing were as follows: 19.9% (36 of 181) for sputum" exact="bacterial" post="culture, 1.8% (3 of 173) for blood culture, 28.3%"/>
 <result pre="of 173) for blood culture, 28.3% (73 of 258) for" exact="respiratory" post="virus polymerase chain reaction (PCR), 1.2% (3 of 258)"/>
 <result pre="urinary Streptococcus pneumoniae antigen, and 0.8% (2 of 258) for" exact="Legionella" post="pneumophila antigen. cEight patients had rhinovirus and S pneumoniae"/>
 <result pre="had parainfluenza and S pneumoniae or H influenzae, 2 had" exact="respiratory" post="syncytial virus and S pneumoniae, 1 had influenza and"/>
 <result pre="1 had S pneumoniae and mycobacterial, and 1 had 2" exact="bacterial" post="pathogens identified. dStreptococcus pneumoniae was detected solely by a"/>
 <result pre="positive urinary antigen test in 54.8% and solely by positive" exact="bacterial" post="culture in sputum samples in 29.0%. eEight rhinovirus A,"/>
 <result pre="Figure 1. Screening and enrollment of patients hospitalized with community-acquired" exact="pneumonia" post="(CAP). The aetiologic type of pneumonia varied by age"/>
 <result pre="patients hospitalized with community-acquired pneumonia (CAP). The aetiologic type of" exact="pneumonia" post="varied by age group (Table 1). Younger patients had"/>
 <result pre="group (Table 1). Younger patients had the highest incidence of" exact="bacterial" post="pneumonia, predominantly due to higher incidence of M pneumoniae"/>
 <result pre="likely to have a pathogen identified. The different types of" exact="pneumonia" post="were not associated with disease severity. Empirical Antibiotic Treatment"/>
 <result pre="identified. The different types of pneumonia were not associated with" exact="disease" post="severity. Empirical Antibiotic Treatment The majority of patients were"/>
 <result pre="or ceftriaxone (8%) with or without doxycycline. Empirical coverage for" exact="atypical" post="pathogens was more common in younger age groups (Table"/>
 <result pre="piperacillin-tazobactam monotherapy without macrolide. Among the 20 patients with nonsevere" exact="pneumonia" post="given nonadherent antibiotics, 7 received piperacillin-tazobactam or meropenem, 8"/>
 <result pre="received amoxicillin-clavulanate/ceftriaxone, with a macrolide, 2 received fluoroquinolone in the" exact="absence of" post="documented allergy to beta-lactam antibiotics, and 3 were not"/>
 <result pre="a macrolide, 2 received fluoroquinolone in the absence of documented" exact="allergy" post="to beta-lactam antibiotics, and 3 were not prescribed any"/>
 <result pre="nonadherent empirical antibiotics was more common in patients with underlying" exact="chronic" post="illnesses (70% vs 53%, P = .013) and more severe disease,"/>
 <result pre="days was associated with older age groups, male sex, underlying" exact="chronic" post="illnesses, absence of pathogen identified, more severe disease, as"/>
 <result pre="associated with older age groups, male sex, underlying chronic illnesses," exact="absence of" post="pathogen identified, more severe disease, as well as nonadherent"/>
 <result pre="of corticosteroid (Supplementary Table 1). After adjustment for age, underlying" exact="chronic" post="illness, and disease severity, length of stay ≥7 days"/>
 <result pre="Table 1). After adjustment for age, underlying chronic illness, and" exact="disease" post="severity, length of stay ≥7 days was independently associated"/>
 <result pre="(adjusted odds ratio, 2.27; 95% confidence interval, 1.02–5.06) and the" exact="absence of" post="pathogen identified (adjusted odds ratio, 2.11; 95% confidence interval,"/>
 <result pre="Mortality at 1 year was associated with older age, underlying" exact="chronic" post="illness, more severe disease, as well as nonadherent empirical"/>
 <result pre="nonadherent empirical antibiotics (Table 2). After adjustment for age, underlying" exact="chronic" post="illness, and disease severity, nonadherent empirical antibiotics was independently"/>
 <result pre="(Table 2). After adjustment for age, underlying chronic illness, and" exact="disease" post="severity, nonadherent empirical antibiotics was independently associated with 1-year"/>
 <result pre=".472 Nursing home resident 3 (1.3%) 1 (4.0%) .336 Underlying" exact="chronic" post="illness 128 (54.9%) 19 (76.0%) .043 Pneumococcal vaccine 76"/>
 <result pre="Antibiotics before admission 36 (17.5%) 1 (5.0%) .211 Type of" exact="Pneumonia" post=" Bacterial 33 (14.2%) 5 (20.0%) .386  Viral 50 (21.5%)"/>
 <result pre="4 (16.0%) .539 Supplementary oxygen 129 (55.4%) 21 (84.0%) .006" exact="Noninvasive" post="ventilation, or intensive care 12 (5.2%) 6 (24.0%) .004"/>
 <result pre="(5.2%) 6 (24.0%) .004 5.52 (1.97–15.45) .001 Empirical coverage for" exact="atypical" post="pathogens 127 (54.5%) 14 (56.0%) .887 Nonadherent empirical antibiotics"/>
 <result pre="to local treatment guidelines. DISCUSSION In this prospective cohort study," exact="viral pneumonia" post="was the most common cause of CAP. The most"/>
 <result pre="local treatment guidelines. DISCUSSION In this prospective cohort study, viral" exact="pneumonia" post="was the most common cause of CAP. The most"/>
 <result pre="was the most common cause of CAP. The most common" exact="bacterial" post="and atypical pathogens were S pneumoniae, H influenzae, and"/>
 <result pre="most common cause of CAP. The most common bacterial and" exact="atypical" post="pathogens were S pneumoniae, H influenzae, and M pneumoniae,"/>
 <result pre="treatment guidelines was associated with better short- and long-term outcomes." exact="Respiratory" post="viruses are increasingly recognized as important, or even predominant,"/>
 <result pre="recognized as important, or even predominant, causes of CAP in" exact="adult" post="and elderly populations [4]. This is partly due to"/>
 <result pre="due to improved detection rates of a wide spectrum of" exact="respiratory" post="viruses using molecular tests performed on upper respiratory tract"/>
 <result pre="wide spectrum of respiratory viruses using molecular tests performed on" exact="upper" post="respiratory tract samples [14]. In our cohort, influenza and"/>
 <result pre="spectrum of respiratory viruses using molecular tests performed on upper" exact="respiratory" post="tract samples [14]. In our cohort, influenza and rhinovirus"/>
 <result pre="[14]. In our cohort, influenza and rhinovirus are the predominant" exact="viral" post="pathogens, similar to other studies of CAP [2]. In"/>
 <result pre="In previous studies, researchers questioned the role of rhinoviruses in" exact="lower" post="respiratory tract infections. More recent studies demonstrated a high"/>
 <result pre="previous studies, researchers questioned the role of rhinoviruses in lower" exact="respiratory" post="tract infections. More recent studies demonstrated a high rate"/>
 <result pre="studies demonstrated a high rate of detection of rhinovirus from" exact="lower" post="respiratory tract samples in patients with severe pneumonia, supporting"/>
 <result pre="demonstrated a high rate of detection of rhinovirus from lower" exact="respiratory" post="tract samples in patients with severe pneumonia, supporting its"/>
 <result pre="In our study and others, up to &amp;gt;20% patients with" exact="viral pneumonia" post="had a bacterial copathogen [4]. This increases the difficulty"/>
 <result pre="our study and others, up to &amp;gt;20% patients with viral" exact="pneumonia" post="had a bacterial copathogen [4]. This increases the difficulty"/>
 <result pre="others, up to &amp;gt;20% patients with viral pneumonia had a" exact="bacterial" post="copathogen [4]. This increases the difficulty in identifying patients"/>
 <result pre="identifying patients not requiring antibacterial coverage in patients with confirmed" exact="viral pneumonia." post="Adopting more sensitive diagnostic tools for detection of bacterial"/>
 <result pre="viral pneumonia. Adopting more sensitive diagnostic tools for detection of" exact="bacterial" post="pathogens, or using serum biomarkers such as procalcitonin, may"/>
 <result pre="[4, 15]. Younger age groups had a higher proportion of" exact="bacterial" post="pneumonia, largely due to higher detection rates of M"/>
 <result pre="was 2 to 12 times higher in younger versus older" exact="adult" post="populations [16, 17]. According to our treatment guideline, coverage"/>
 <result pre="populations [16, 17]. According to our treatment guideline, coverage for" exact="atypical" post="pathogens is optional for patients with nonsevere disease [5]."/>
 <result pre="coverage for atypical pathogens is optional for patients with nonsevere" exact="disease" post="[5]. Such coverage should be strongly recommended for younger"/>
 <result pre="strongly recommended for younger patients. On the other hand, a" exact="lower" post="rate of pathogen detection was observed in elderly patients."/>
 <result pre="a recent study, dysbiosis of the normal flora in the" exact="respiratory" post="tract, which allows overgrowth of 1 or more of"/>
 <result pre="study supported our current treatment guidelines [5]. First, 93% of" exact="bacterial" post="pathogens were susceptible to amoxicillin-clavulanate, and M pneumoniae was"/>
 <result pre="susceptible to amoxicillin-clavulanate, and M pneumoniae was the most common" exact="atypical" post="pathogen, supporting the recommendation of amoxicillin-clavulanate and doxycycline for"/>
 <result pre="of amoxicillin-clavulanate and doxycycline for hospitalized nonsevere CAP. Macrolide resistance" exact="secondary" post="to A2063G mutation among M pneumoniae isolates was present"/>
 <result pre="using contemporary methods of pathogen identification [2, 4]. In the" exact="absence of" post="pathogen-guided therapy, good clinical outcomes would heavily rely on"/>
 <result pre="with decreased time to clinical stability, shorter duration of hospitalization," exact="lower" post="in-hospital mortality, lower costs, and improved quality of life"/>
 <result pre="to clinical stability, shorter duration of hospitalization, lower in-hospital mortality," exact="lower" post="costs, and improved quality of life compared with over-"/>
 <result pre="mechanisms include the impact of antibiotics on the risk of" exact="recurrent" post="infections due to resistant pathogens and level of persistent"/>
 <result pre="include the impact of antibiotics on the risk of recurrent" exact="infections" post="due to resistant pathogens and level of persistent inflammation"/>
 <result pre="local guidelines involved both &quot;overtreatment�? (broad-spectrum antibiotics prescribed in the" exact="absence of" post="relevant indications) and &quot;undertreatment�? (inadequate coverage for potential drug-resistant"/>
 <result pre="(inadequate coverage for potential drug-resistant pathogens in patients with severe" exact="pneumonia" post="or underlying bronchiectasis). In patients at low risk of"/>
 <result pre="pneumonia or underlying bronchiectasis). In patients at low risk of" exact="infection" post="due to drug-resistant pathogens, overtreatment with broad-spectrum antibiotics (with"/>
 <result pre="the other hand, undertreatment was observed in patients with severe" exact="pneumonia" post="or bronchiectasis who were prescribed beta-lactam antibiotics in the"/>
 <result pre="hand, undertreatment was observed in patients with severe pneumonia or" exact="bronchiectasis" post="who were prescribed beta-lactam antibiotics in the absence of"/>
 <result pre="pneumonia or bronchiectasis who were prescribed beta-lactam antibiotics in the" exact="absence of" post="macrolide combination therapy. Because only 7% of bacterial pathogens"/>
 <result pre="the absence of macrolide combination therapy. Because only 7% of" exact="bacterial" post="pathogens were nonsusceptible to amoxicillin-clavulanate in our cohort, the"/>
 <result pre="macrolide was possibly the major factor accounting for worse outcomes." exact="Multiple" post="studies have shown better outcomes in moderate-to-severe pneumonia with"/>
 <result pre="worse outcomes. Multiple studies have shown better outcomes in moderate-to-severe" exact="pneumonia" post="with the combination of beta-lactam and macrolide, compared with"/>
 <result pre="[4]. In our cohort, among those with empirical coverage for" exact="atypical" post="pathogens, 88% were given doxycycline. The use of doxycycline"/>
 <result pre="part of a combination therapy for CAP for coverage of" exact="atypical" post="pathogens was less well evaluated, compared with macrolide or"/>
 <result pre="atypical pathogens was less well evaluated, compared with macrolide or" exact="respiratory" post="fluoroquinolones [4]. In a retrospective study in San Francisco,"/>
 <result pre="with CAP [22]. Doxycycline is recommended for coverage of certain" exact="atypical" post="pathogens, such as macrolide-resistant M pneumoniae or Coxiella burnetii,"/>
 <result pre="macrolide or fluoroquinolone resistance in S pneumoniae [23, 24] or" exact="tuberculosis" post="are prevalent [25]. Our results and others supported that"/>
 <result pre="for nonsevere CAP in regions with high macrolide resistance in" exact="atypical" post="pathogens. However, the role of doxycycline in severe pneumonia"/>
 <result pre="in atypical pathogens. However, the role of doxycycline in severe" exact="pneumonia" post="is uncertain and needs further evaluation. There are some"/>
 <result pre="our analyses. We did not perform PCR testing for some" exact="atypical" post="pathogens, including Legionella species and C burnetii; thus, we"/>
 <result pre="did not perform PCR testing for some atypical pathogens, including" exact="Legionella" post="species and C burnetii; thus, we may have underestimated"/>
 <result pre="thus, we may have underestimated the proportions of patients with" exact="atypical" post="pathogens. This study was conducted over an 18-month period,"/>
 <result pre="causes epidemics every 3 to 7 years [16]. The relatively" exact="short" post="duration did not allow us to evaluate seasonality of"/>
 <result pre="in 45% of patients hospitalized with CAP in Hong Kong." exact="Viral" post="pneumonia was most common. Influenza virus, S pneumoniae, and"/>
 <result pre="45% of patients hospitalized with CAP in Hong Kong. Viral" exact="pneumonia" post="was most common. Influenza virus, S pneumoniae, and M"/>
 <result pre="and M pneumoniae were the most common viral, bacterial, and" exact="atypical" post="pathogens, respectively, supporting our treatment guidelines. Almost all bacterial"/>
 <result pre="and atypical pathogens, respectively, supporting our treatment guidelines. Almost all" exact="bacterial" post="pathogens were susceptible to amoxicillin-clavulanate, supporting its role as"/>
 <result pre="survival. Supplementary Data Supplementary materials are available at Open Forum" exact="Infectious" post="Diseases online. Consisting of data provided by the authors"/>
 <result pre="Supplementary Data Supplementary materials are available at Open Forum Infectious" exact="Diseases" post="online. Consisting of data provided by the authors to"/>
 <result pre="Health and Medical Research Fund Commissioned Research on Control of" exact="Infectious" post="Diseases (CU-17-A16). Potential conflicts of interest. M. I. has"/>
 <result pre="and Medical Research Fund Commissioned Research on Control of Infectious" exact="Diseases" post="(CU-17-A16). Potential conflicts of interest. M. I. has received"/>
 <result pre="territories, 1980–2017: a systematic analysis for the Global Burden of" exact="Disease" post="Study 2017. Lancet2018; 392:1736–88.30496103 2.JainS, SelfWH, WunderinkRG, et al.Community-acquired"/>
 <result pre="Disease Study 2017. Lancet2018; 392:1736–88.30496103 2.JainS, SelfWH, WunderinkRG, et al.Community-acquired" exact="pneumonia" post="requiring hospitalization among U.S. adults. N Engl J Med2015;"/>
 <result pre="U.S. adults. N Engl J Med2015; 373:415–27.26172429 3.SongJH, HuhK, ChungDRCommunity-acquired" exact="pneumonia" post="in the Asia-Pacific region. Semin Respir Crit Care Med2016;"/>
 <result pre="37:839–54.27960208 4.WunderinkRG, WatererGAdvances in the causes and management of community" exact="acquired" post="pneumonia in adults. BMJ2017; 358:j2471.28694251 5.HoPL, WuTC, ChaoDVK, et"/>
 <result pre="4.WunderinkRG, WatererGAdvances in the causes and management of community acquired" exact="pneumonia" post="in adults. BMJ2017; 358:j2471.28694251 5.HoPL, WuTC, ChaoDVK, et al.Reducing"/>
 <result pre="in adults. BMJ2017; 358:j2471.28694251 5.HoPL, WuTC, ChaoDVK, et al.Reducing Bacterial" exact="Resistance" post="with IMPACT. 5th edHong Kong: Centrefor Health Protection, Hong"/>
 <result pre="January 2020. 6.LimWS, van der EerdenMM, LaingR, et al.Defining community" exact="acquired" post="pneumonia severity on presentation to hospital: an international derivation"/>
 <result pre="2020. 6.LimWS, van der EerdenMM, LaingR, et al.Defining community acquired" exact="pneumonia" post="severity on presentation to hospital: an international derivation and"/>
 <result pre="al.Value of serum procalcitonin, neopterin, and C-reactive protein in differentiating" exact="bacterial" post="from viral etiologies in patients presenting with lower respiratory"/>
 <result pre="serum procalcitonin, neopterin, and C-reactive protein in differentiating bacterial from" exact="viral" post="etiologies in patients presenting with lower respiratory tract infections."/>
 <result pre="in differentiating bacterial from viral etiologies in patients presenting with" exact="lower" post="respiratory tract infections. Diagn Microbiol Infect Dis2007; 59:131–6.17662560 8.WinchellJM,"/>
 <result pre="differentiating bacterial from viral etiologies in patients presenting with lower" exact="respiratory" post="tract infections. Diagn Microbiol Infect Dis2007; 59:131–6.17662560 8.WinchellJM, ThurmanKA,"/>
 <result pre="study. J Crit Care2018; 43:183–9.28915392 14.KarhuJ, Ala-KokkoTI, VuorinenT, et al.Lower" exact="respiratory" post="tract virus findings in mechanically ventilated patients with severe"/>
 <result pre="Infect Dis2014; 59:62–70.24729498 15.TorresA, LeeN, CillonizC, et al.Laboratory diagnosis of" exact="pneumonia" post="in the molecular age. Eur Respir J2016; 48:1764–78.27811073 16.HoPL,"/>
 <result pre="LaJoieAS, BrockGN, et al.Improving outcomes in elderly patients with community-acquired" exact="pneumonia" post="by adhering to national guidelines: community-acquired pneumonia organization international"/>
 <result pre="patients with community-acquired pneumonia by adhering to national guidelines: community-acquired" exact="pneumonia" post="organization international cohort study results. Arch Intern Med2009; 169:1515–24.19752410"/>
 <result pre="VallèsX, et al.Adherence to guidelines’ empirical antibiotic recommendations and community-acquired" exact="pneumonia" post="outcome. Eur Respir J2008; 32:892–901.18550608 20.MenéndezR, ReyesS, MartínezR, et"/>
 <result pre="Infect2012; 18:E71–3.22284533 23.CharlesPG, WhitbyM, FullerAJ, et al.The etiology of community-acquired" exact="pneumonia" post="in Australia: why penicillin plus doxycycline or a macrolide"/>
 <result pre="WongRY, LiF, et al.High mortality in adults hospitalized for active" exact="tuberculosis" post="in a low HIV prevalence setting. PLoS One2014; 9:e92077.24642794"/>
</results>
